Report Descriptions:

The Global Transthyretin Amyloidosis Treatment Market was estimated at USD 3.24 billion in 2025 and is projected to reach USD 7.29 billion by 2034, reflecting a robust CAGR of 15.11% over the forecast period from 2025 to 2034. The Transthyretin Amyloidosis Treatment market report offers a comprehensive and nuanced view of the industry, moving beyond conventional analysis. It provides a thorough examination of the markets dynamics, encompassing a detailed exploration of the factors propelling growth, such as evolving economic conditions, advancements in technology, shifts in regulatory policies, and changes in consumer behavior. Furthermore, the report discusses the projected Compound Annual Growth Rate (CAGR), providing stakeholders with a clear understanding of the market's expected growth trajectory and offering data-driven insights into future market dynamics.

The Transthyretin Amyloidosis Treatment market under analysis is characterized by dynamic growth and evolving trends that are reshaping the competitive landscape. With 2023 serving as the base year for this Transthyretin Amyloidosis Treatment market study, recent data highlights a significant expansion driven by technological advancements, rising consumer demand, and a growing focus on innovation. Companies are refining their go-to-market (GTM) strategies to effectively capture these emerging opportunities and respond to the rapidly changing market dynamics.

Key trends influencing the Transthyretin Amyloidosis Treatment market include the rapid adoption of digital technologies, the integration of sustainable practices, and the increasing importance of customer experience. These trends are not only driving growth but also creating new challenges for industry participants, who must adapt their GTM strategies to navigate regulatory changes, supply chain disruptions, and fluctuating economic conditions. Despite these challenges, the Transthyretin Amyloidosis Treatment market is poised for sustained growth, with emerging markets playing a critical role in the expansion of the industry.

Looking ahead, the Transthyretin Amyloidosis Treatment market is forecasted to continue its upward momentum through 2034, supported by ongoing investments in research and development, strategic partnerships, and mergers and acquisitions. Companies that can effectively tailor their GTM strategies to the evolving market landscape, innovate, and meet shifting consumer demands are likely to achieve sustained success. Transthyretin Amyloidosis Treatment market report provides a comprehensive analysis of the current market environment and offers valuable insights into the key drivers, challenges, and opportunities that will shape the industry's future over the next decade.This report offers a comprehensive analysis of market dynamics across various segments, regions, and countries, incorporating both qualitative and quantitative data. It covers the period from 2017 to 2034, providing a detailed examination of historical performance, current market conditions, and future projections.

Historical Analysis (2017-2023): The report presents a thorough review of market trends, performance metrics, and growth trajectories for the years 2017 through 2023. This historical perspective is crucial for understanding past market behavior and identifying patterns that influence current and future market dynamics.

Forecast and Projections (2025-2034): Building on historical data, the report provides forward-looking insights, including market forecasts and growth projections from 2023 to 2034. It details anticipated market trends, emerging opportunities, and potential challenges across different segments, regions, and countries.

Compound Annual Growth Rate (CAGR): The report includes a precise calculation of the compound annual growth rate (CAGR) for the forecast period of 2025 to 2034. This metric will be instrumental in assessing the expected growth trajectory and the overall market potential during the forecast period.

The Transthyretin Amyloidosis (ATTR) Treatment Market is expanding steadily, driven by increased awareness, advancements in genetic testing, and the approval of novel therapies. ATTR is a rare and progressive condition, primarily affecting the heart and peripheral nerves, with two forms: hereditary (hATTR) and wild-type (wtATTR). The emergence of disease-modifying therapies such as Tafamidis, Patisiran, and Inotersen has significantly improved patient outcomes and broadened treatment options.

From an insights perspective, pharmaceutical companies are focusing on RNA interference and antisense oligonucleotide-based therapies to halt transthyretin protein accumulation. Theres also a push for early diagnosis and targeted therapy, which has led to a growing demand for companion diagnostics. Increasing participation in clinical trials, particularly in the U.S. and Europe, is encouraging market entry of pipeline drugs expected to reshape the treatment landscape in the coming years.

Country-level analysis shows the United States as the market leader due to early drug approvals, high diagnosis rates, and supportive regulatory frameworks. European countries, especially Germany, France, and the UK, are following closely with robust clinical infrastructure and reimbursement mechanisms. In Asia-Pacific, Japan has shown proactive efforts in ATTR diagnosis and treatment, while awareness in other countries is gradually rising.

Regionally, North America dominates the market owing to advanced healthcare systems and high per capita health expenditure. Europe is witnessing growth through clinical research collaborations and access to orphan drug incentives. The Asia-Pacific region is emerging, with increased healthcare investments and rising awareness of rare diseases. Latin America and the Middle East & Africa remain underpenetrated markets but show long-term potential as diagnostic capabilities improve.

R&D Pipeline Expansion: Leading players are investing heavily in late-stage clinical trials for novel RNA-based and gene-silencing therapies.

Strategic Collaborations: Pharma-biotech partnerships are accelerating development and commercialization of ATTR-specific drugs globally.

Market Access Initiatives: Companies are working with health authorities to ensure faster approvals and reimbursement in key markets.

Patient Support Programs: Programs focused on diagnosis, education, and treatment affordability are increasing patient retention and compliance.

Study Period for the Transthyretin Amyloidosis Treatment Market:

Transthyretin Amyloidosis Treatment Market

Report Highlights:

Our team of experienced researchers has meticulously gathered and analyzed data to deliver a thorough examination of market dynamics, competitive landscape, and emerging technologies. With a focus on delivering actionable intelligence, this report aims to empower decision-makers with the information needed to make informed choices and stay ahead of the competition. Whether you are a seasoned industry player or a new entrant, our market research report serves as a strategic tool to navigate the complexities of the market, aiding in successful business planning and growth strategies.

Key Chapters of our Transthyretin Amyloidosis Treatment Market Report includes:

Market Dynamics, Variables, and Industry Analysis:

This chapter of our Transthyretin Amyloidosis Treatment market report provides an in-depth examination of the factors shaping the industry landscape. This section typically encompasses several key elements to offer a comprehensive understanding of the industry landscape such as market drivers & restraints analysis, market opportunities & trend analysis, market size & growth analysis, competitive analysis, SWOT analysis, business environment tools such as Porter's five forces & PESTEL analysis, Ansoff Matrix analysis, penetration & growth prospect analysis, regulatory framework & reimbursement scenario analysis, impact of macro & micro economic factors analysis such as Covid-19 impact, GDP growth, market inflation, U.S.- China trade war, Russia-Ukraine war impact, and supply chain analysis.

Segment Analysis & Forecast to 2034:

The segment analysis chapter of Transthyretin Amyloidosis Treatment market report is a critical section that delves into a detailed examination of the market's various segments. Segmentation involves dividing the market into distinct categories based on certain criteria to better understand and address the diverse needs of consumers. This chapter typically follows the introduction and provides a more granular view of the market, offering valuable insights for businesses and stakeholders. The components of the chapter lude segment definitions to understand the inclusions and exclusions of the study, assumptions, market size estimates and growth trend analysis of each segment, qualitative analysis of the segment, technological advancements, market penetration rate, market adoption rate, market share examination by each segment, segment growth drivers and restraint barriers, consumer behaviour and challenge analysis.

Regional Market Analysis & Forecast to 2034:

The chapter in Transthyretin Amyloidosis Treatment market research report is a pivotal section that examines and predicts the market dynamics and trends specific to different geographical regions. This chapter is crucial for businesses and stakeholders seeking a comprehensive understanding of how the market behaves across various locations, enabling them to tailor strategies and make informed decisions based on regional variations. The regional analysis chapter of our Transthyretin Amyloidosis Treatment market report is classified into regions & country-level. The chapter consists of North America (U.S., Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Sweden, Denmark, Norway, Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, Thailand, Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, Colombia, Rest of Latin America), Middle East & Africa (South Africa, Saudi Arabia, UAE, Kuwait, Rest of Middle East & Africa).

Transthyretin Amyloidosis Treatment Market

Competitive Analysis & Company Profiles:

This section of a Transthyretin Amyloidosis Treatment market report is a crucial segment that provides a comprehensive overview of the competitive landscape within the market. This section is vital for businesses, investors, and stakeholders seeking insights into key players, their market positioning, strengths, weaknesses, strategies, and potential impacts on the overall market dynamics. The chapter includes research methodology used to analyse the market competition, list of key players operating in the market, detailed company profile section which includes company overview, business verticals, financial performance, product/services benchmarking, geographical presence, and strategic initiatives.

Key Players Operating in the Transthyretin Amyloidosis Treatment Market are as follows:

• Pfizer Inc. Market leader with Vyndaqel/Vyndamax (tafamidis).
• Alnylam Pharmaceuticals Developer of Onpattro (patisiran) and Amvuttra (vutrisiran) for hATTR.
• Ionis Pharmaceuticals Advanced antisense therapies for ATTR.
• Eidos Therapeutics (a BridgeBio company) Investigational therapy AG10 (acoramidis).
• Intellia Therapeutics Involved in in vivo CRISPR gene-editing for ATTR (NTLA-2001).
• AstraZeneca Investing in ATTR R&D via partnerships.
• Prothena Corporation Focused on antibody-based therapies targeting TTR amyloid.
• Regeneron Pharmaceuticals
• Silence Therapeutics
• Neurimmune AG
• SomaLogic Inc.
• Akcea Therapeutics (acquired by Ionis)
• Viatris Inc.

Transthyretin Amyloidosis Treatment Market

Report Scope:

Quintile Reports has segmented the Transthyretin Amyloidosis Treatment market into the following segments:

Based on Disease Type, the Transthyretin Amyloidosis Treatment market is segmented into:

• Hereditary ATTR (hATTR)
• Wild-type ATTR (wtATTR)

Based on Treatment Type, the Transthyretin Amyloidosis Treatment market is segmented into:

• TTR Stabilizers (e.g., Tafamidis)
• TTR Gene Silencers (e.g., siRNA, ASO)
• Monoclonal Antibodies
• Supportive Therapies
• Heart and/or Liver Transplantation

Based on Route of Administration, the Transthyretin Amyloidosis Treatment market is segmented into:

• Oral
• Intravenous
• Subcutaneous

Based on End User, the Transthyretin Amyloidosis Treatment market is segmented into:

• Hospitals
• Specialty Clinics
• Academic & Research Institutes
• Homecare Settings

Report Scope	Details
Report Version	2024
Growth Rate	CAGR of 15.11% from 2025 to 2034
Base year	2024
Actual estimates/Historical data	2017 - 2023
Forecast period	2025 - 2034
Quantitative units	Revenue in USD million/billion & CAGR from 2025 to 2034
Country scope	North America (U.S., Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Sweden, Denmark, Norway, Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, Thailand, Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, Colombia, Rest of Latin America), Middle East & Africa (South Africa, Saudi Arabia, UAE, Kuwait, Rest of Middle East & Africa).
The Segment covered by Disease Type	Hereditary ATTR (hATTR) Wild-type ATTR (wtATTR)
The Segment covered by Treatment Type	TTR Stabilizers (e.g., Tafamidis) TTR Gene Silencers (e.g., siRNA, ASO) Monoclonal Antibodies Supportive Therapies Heart and/or Liver Transplantation
Companies covered	Pfizer Inc. Market leader with Vyndaqel/Vyndamax (tafamidis). Alnylam Pharmaceuticals Developer of Onpattro (patisiran) and Amvuttra (vutrisiran) for hATTR. Ionis Pharmaceuticals Advanced antisense therapies for ATTR. Eidos Therapeutics (a BridgeBio company) Investigational therapy AG10 (acoramidis). Intellia Therapeutics Involved in in vivo CRISPR gene-editing for ATTR (NTLA-2001). AstraZeneca Investing in ATTR R&D via partnerships. Prothena Corporation Focused on antibody-based therapies targeting TTR amyloid. Regeneron Pharmaceuticals Silence Therapeutics Neurimmune AG SomaLogic Inc. Akcea Therapeutics (acquired by Ionis) Viatris Inc.
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Free customization scope (equivalent to 5 analyst working days)	If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of the customization

Key Reasons to Acquire the Transthyretin Amyloidosis Treatment Market Research Report:

• This report offers a comprehensive analysis of the Transthyretin Amyloidosis Treatment market from 2017 to 2034, including market segments, current trends, estimations, and dynamics
• It also provides information on key drivers, restraints, and opportunities
• Porter's five forces analysis is used to assess the potency of buyers and suppliers, helping stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network
• The report includes an in-depth analysis of the Transthyretin Amyloidosis Treatment market segmentation to identify prevailing market opportunities
• Major countries in each region are mapped according to their revenue contribution to the global market
• Market player positioning is also analyzed to facilitate benchmarking and provide a clear understanding of the present position of the market players
• The report includes an analysis of the regional and global Transthyretin Amyloidosis Treatment market trends, key players, market segments, application areas, and market growth strategies

Transthyretin Amyloidosis Treatment Market

Available Customizations:

With the given market data, Quintile Reports offers customizations according to the company's specific needs. The following customization options are available for the report:

• You may ask for a global, regional, or country-specific report.
• You may ask if there are any particular types, applications, or products on which you would like to focus.
• You may ask for specific competitors/players to be profiled.

Transthyretin Amyloidosis Treatment Market Report

Statistics for the 2024 Transthyretin Amyloidosis Treatment market share, size, and revenue growth rate were created by Quintile Report™. Transthyretin Amyloidosis Treatment analysis includes a market forecast outlook for 2034 and a historical overview. Get a free PDF sample of this market analysis, please get in touch with our principal analyst at sales@quintilereports.com